A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - Sep 4, 2026 - P1 | N=42 | Recruiting | Sponsor: Astellas Institute for Regenerative Medicine | Trial completion date: Jun 2026 ➔ Dec 2027 | Trial primary completion date: Jun 2026 ➔ Dec 2027
Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
|